Literature DB >> 18432600

First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.

K O Kagan1, D Wright, K Spencer, F S Molina, K H Nicolaides.   

Abstract

OBJECTIVES: To use multiple regression analysis to define the contribution of maternal variables that influence the measured concentration of free beta-human chorionic gonadotropin (beta-hCG) and pregnancy-associated plasma protein-A (PAPP-A), and the interaction between these covariates, in first-trimester biochemical screening for trisomy 21.
METHODS: This was a multicenter study of prospective screening for trisomy 21 by a combination of fetal nuchal translucency thickness, and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks of gestation. In the pregnancies subsequently found to have trisomy 21 and in those with no obvious chromosomal abnormality, we used multiple regression analysis to account for pregnancy characteristics that influence the measured concentrations of free beta-hCG and PAPP-A. We fitted Gaussian distributions to the distribution of log multiples of the median (MoM) values in trisomy 21 and in unaffected pregnancies.
RESULTS: There were 491 cases of trisomy 21 and 96 803 chromosomally normal pregnancies. Compared with values in Caucasian women, those who were parous, non-smokers and those who conceived spontaneously, PAPP-A was 57% higher in women of Afro-Caribbean origin, 3% higher in South Asians, 9% higher in East Asians, 2% higher in nulliparous women, 17% lower in smokers and 10% lower in those conceiving by in-vitro fertilization (IVF). Free beta-hCG was 12% higher in women of Afro-Caribbean origin, 9% lower in South Asians, 8% higher in East Asians, 2% higher in nulliparous women, 4% lower in smokers and 9% higher in those conceiving by IVF. In screening for trisomy 21 by maternal age and serum free beta-hCG and PAPP-A the estimated detection rate was 65% for a false-positive rate of 5%.
CONCLUSIONS: In first-trimester biochemical screening for trisomy 21 it is essential to adjust the measured values of free beta-hCG and PAPP-A for maternal and pregnancy characteristics. Copyright (c) 2008 ISUOG

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18432600     DOI: 10.1002/uog.5332

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  24 in total

1.  The maternal plasma proteome changes as a function of gestational age in normal pregnancy: a longitudinal study.

Authors:  Roberto Romero; Offer Erez; Eli Maymon; Piya Chaemsaithong; Zhonghui Xu; Percy Pacora; Tinnakorn Chaiworapongsa; Bogdan Done; Sonia S Hassan; Adi L Tarca
Journal:  Am J Obstet Gynecol       Date:  2017-03-03       Impact factor: 8.661

2.  Low first-trimester PAPP-A in IVF (fresh and frozen-thawed) pregnancies, likely due to a biological cause.

Authors:  Lauren P Hunt; A M McInerney-Leo; S Sinnott; B Sutton; R Cincotta; G Duncombe; J Chua; M Peterson
Journal:  J Assist Reprod Genet       Date:  2017-07-17       Impact factor: 3.412

Review 3.  First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free β-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome.

Authors:  S Shiefa; M Amargandhi; J Bhupendra; S Moulali; T Kristine
Journal:  Indian J Clin Biochem       Date:  2012-10-12

4.  Two Consecutive Pregnancies with Simpson-Golabi-Behmel Syndrome Type 1: Case Report and Review of Published Prenatal Cases.

Authors:  Konstantin Ridnõi; Elvira Kurvinen; Sander Pajusalu; Tiia Reimand; Katrin Õunap
Journal:  Mol Syndromol       Date:  2018-06-08

5.  First trimester combined screening in patients with systemic lupus erythematosus: impact of pre-analytical variables on risk assessment.

Authors:  Maria José Rego de Sousa; Rita Ribeiro; Argyro Syngelaki; Kypros H Nicolaides
Journal:  Clin Rheumatol       Date:  2019-03-28       Impact factor: 2.980

6.  Involvement of the HERV-derived cell-fusion inhibitor, suppressyn, in the fusion defects characteristic of the trisomy 21 placenta.

Authors:  Jun Sugimoto; Danny J Schust; Tomomi Yamazaki; Yoshiki Kudo
Journal:  Sci Rep       Date:  2022-06-22       Impact factor: 4.996

7.  Levels of CEA, CA153, CA199, CA724 and AFP in nipple discharge of breast cancer patients.

Authors:  Song Zhao; Yu Mei; Yongmei Wang; Jiang Zhu; Guixi Zheng; Rong Ma
Journal:  Int J Clin Exp Med       Date:  2015-11-15

8.  Birth weight, breast cancer and the potential mediating hormonal environment.

Authors:  Radek Bukowski; Rowan T Chlebowski; Inger Thune; Anne-Sofie Furberg; Gary D V Hankins; Fergal D Malone; Mary E D'Alton
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

Review 9.  First trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-11-30

10.  First Trimester Aneuploidy Screening Markers in Women with Pre-Gestational Diabetes Mellitus.

Authors:  Padmalatha Gurram; Peter Benn; James Grady; Anne-Marie Prabulos; Winston Campbell
Journal:  J Clin Med       Date:  2014-05-08       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.